Yan-Xin Liang

CD4+ T-Cell Program Dynamics Under PD-1/PD-L1 Blockade in NSCLC

Immune checkpoint blockade (ICB) targeting PD-1/PDL1 has transformed non-small cell lung cancer (NSCLC) therapy, yet durable benefit remains limited to a subset of patients. While most mechanistic and biomarker frameworks emphasize CD8+ T cells, accumulating single-cell, TCR, and spatial evidence indicates that CD4+ T...